{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:44:23Z","timestamp":1793198663823,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40265-020-01330-y","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T12:03:05Z","timestamp":1590753785000},"page":"923-929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["Pemigatinib: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"issue":"6","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","volume":"145","author":"S Rizvi","year":"2013","unstructured":"Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215\u201329.","journal-title":"Gastroenterology."},{"key":"1330_CR2","unstructured":"US National Library of Medicine. Genetics Home Reference: Cholangiocarcinoma. 2020;2020."},{"key":"1330_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","volume":"3","author":"A Pellino","year":"2018","unstructured":"Pellino A, Loupakis F, Cadamuro M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018;3:40.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1330_CR4","unstructured":"Incyte Corporation. PEMAZYRE\u2122 (pemigatinib) tablets, for oral use: US prescribing information. 2020. http:\/\/www.fda.gov\/. Accessed 28 Apr 2020."},{"key":"1330_CR5","unstructured":"Incyte Corporation. FDA approves Incyte\u2019s Pemazyre\u2122 (pemigatinib) as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma [media release]. 17 Apr 2020. http:\/\/www.incyte.com."},{"key":"1330_CR6","unstructured":"US FDA. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion [media release]. 17 Apr 2020. http:\/\/www.fda.gov\/."},{"key":"1330_CR7","unstructured":"US FDA. Orphan drug designations and approvals. 2019. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm. Accessed 08 May 2020."},{"key":"1330_CR8","unstructured":"Incyte Corporation. Incyte and Foundation Medicine announce agreement to develop companion diagnostic for pemigatinib (INCB54828), a selective FGFR inhibitor, in patients with cholangiocarcinoma [media release]. 11 Apr 2018. http:\/\/www.incyte.com."},{"key":"1330_CR9","unstructured":"Incyte Corporation. Innovent and Incyte announce strategic collaboration and licensing agreement for three clinical-stage product candidates in China [media release]. 16 Dec 2018. http:\/\/www.incyte.com."},{"issue":"4","key":"1330_CR10","doi-asserted-by":"publisher","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","volume":"15","author":"PCC Liu","year":"2020","unstructured":"Liu PCC, Koblish H, Wu L, et al. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One. 2020;15(4):e0231877.","journal-title":"PLoS One."},{"key":"1330_CR11","doi-asserted-by":"crossref","unstructured":"Subbiah V, Barve M, Iannotti N, et al. FIGHT-101: a phase 1\/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies [abstract no. A078]. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2019.","DOI":"10.1158\/1535-7163.TARG-19-A078"},{"key":"1330_CR12","doi-asserted-by":"crossref","unstructured":"Kuboki Y, Furukawa M, Takahashi Y, et al. Preliminary results from FIGHT-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies [abstract no. P1-156]. Ann Oncol. 2019;30(Suppl 6):vi125.","DOI":"10.1093\/annonc\/mdz343.034"},{"key":"1330_CR13","doi-asserted-by":"crossref","unstructured":"Necchi A, Pouessel D, Leibowitz-Amit R, et al. Interim results of FIGHT-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)\/FGF receptor (FGFR) genetic alterations (GA) [abstract no. 900P]. Ann Oncol. 2018;29(Suppl 8):viii319\u2013viii20.","DOI":"10.1093\/annonc\/mdy283.109"},{"issue":"5","key":"1330_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol."},{"key":"1330_CR15","unstructured":"Foundation Medicine. Foundation Medicine receives FDA approval for FoundationOne(Rm)CDx as the companion diagnostic for Pemazyre(Tm) (pemigatinib), the first FDA-approved targeted therapy for adults with previously treated locally advanced or metastatic cholangiocarcinoma [media release]. 17 Apr 2020. http:\/\/www.foundationmedicine.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01330-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01330-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01330-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T23:30:47Z","timestamp":1622244647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01330-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01330-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"29 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}